[Medicine News] Shanghai Pharmaceutical antidepressant first passed the consistency evaluation; Taiji group obtained the drug approval, and is carrying out the consistency evaluation, and strongly attacked the antibiotic drug market

Shanghai Pharmaceutical fluoxetine hydrochloride capsule first passed the consistency evaluation On August 14, Shanghai Pharmaceutical released a notice that Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd (hereinafter referred to as "Sinopharm"), a holding subsidiary, received the approval document for supplementary drug application issued by the State Drug Administration on fluoxetine hydrochloride capsule (hereinafter referred to as "the drug"), which passed the consistency evaluation of generic drugs According to the pharmaceutical intelligence data query, at present, Shanghai Pharmaceutical Group is the only one applying for the consistency evaluation of the drug, which makes Shanghai Pharmaceutical become the first one to pass and occupy the market advantage The basic information of the drug is as follows: Fluoxetine Hydrochloride capsule is an antidepressant, which was developed by Lilly company in the United States and was first listed in Belgium at the end of 1986 In January 2018, Sinopharm applied to SFDA for conformity evaluation of generic drugs and was accepted According to CHPA data, in 2017, the purchase amount of fluoxetine hydrochloride capsules in hospitals reached 71.61 million yuan, of which the sales of Chinese and Western medicine accounted for 1.77% As of the announcement date, the company has invested about 3.9372 million yuan in the R & D cost for the consistency evaluation of the drug On August 14, Taiji group approved cefuroxime sodium for injection Chongqing Taiji industry (Group) announced that its holding subsidiary Southwest Pharmaceutical Co., Ltd (hereinafter referred to as Southwest Pharmaceutical) recently received the approval document for drug registration of cefuroxime sodium for injection approved and issued by the State Food and drug administration The basic situation of drug approval is as follows: cefuroxime is a bactericidal cephalosporin antibiotic, which can resist most β - lactamases and is effective for a variety of gram-positive and Gram-negative bacteria When the infected bacteria are not clear or caused by sensitive bacteria, it is suitable for treatment There are differences in the sensitivity of cefuroxime sodium It is necessary to consult the applicable geographic, time and local sensitivity data In addition, it can effectively prevent postoperative infection of many operations Generally speaking, cefuroxime alone can work, but when appropriate, it can be combined with aminoglycoside antibiotics or metronidazole (oral, suppository or injection) Cefuroxime may be used in combination with metronidazole when the infection is / or is suspected to be a combination of aerobic and anaerobic bacteria (e.g., peritonitis, aspiration pneumonia, lung, pelvic and brain abscesses), or when such a combination may occur (e.g., in colon or gynecological surgery) According to Yaozhi data, there are 310 domestic approvals for cefuroxime sodium for injection, including many well-known large enterprises, such as China Resources Sanjiu, Guoyao group, Lizhu group, Shenzhen xinlitai, Guangzhou Baiyunshan, etc In addition, it is reported that the sales amount of cefuroxime in the national sample hospital in 2017 was RMB 550 million, accounting for about 4.35% of cephalosporins Among them, cefuroxime sodium for injection is 458 million yuan, accounting for 82.5% of all dosage forms of cefuroxime China's antibiotic drug market is huge, but there are many competing companies If we want to obtain good competitiveness in the market, we need to see the follow-up product quality, efficacy and marketing specific situation According to the announcement, Taiji Group is currently carrying out the consistency evaluation of the drug If it passes, the market situation will be better Information source: Pharmaceutical intelligence data, announcement of Listed Enterprises